4//SEC Filing
Smith Michael David 4
Accession 0001209191-21-037889
CIK 0001348911other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 6:28 PM ET
Size
9.4 KB
Accession
0001209191-21-037889
Insider Transaction Report
Form 4
Smith Michael David
Sr. VP, Development
Transactions
- Sale
Common Stock
2021-06-01$26.83/sh−7,500$201,221→ 0 total - Exercise/Conversion
Common Stock
2021-06-01$8.39/sh+7,500$62,925→ 7,500 total - Exercise/Conversion
Stock Option (right to buy)
2021-06-01−7,500→ 22,596 totalExercise: $8.39Exp: 2026-11-21→ Common Stock (7,500 underlying)
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.22 to $27.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The option is fully vested.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001777800
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 6:28 PM ET
- Size
- 9.4 KB